-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:12 GMT
… non-small cell lung cancer following surgery and … Platform (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … protein-bound, or gemcitabine and carboplatin) were …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:06 GMT
… non-small cell lung cancer following surgery and … Platform (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … protein-bound, or gemcitabine and carboplatin) were …
-
Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
06 Jan 2023 12:27 GMT
… in patients with advanced lung cancer, particularly those receiving … of platinum and gemcitabine was used the … lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res … survival of resected lung cancer independently of tumor …
-
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
04 Jan 2023 12:00 GMT
… in combination with gemcitabine for non-small cell lung cancer (NSCLC).
“This Phase … monotherapy and in combination with gemcitabine. We believe that there could …
-
AstraZeneca: Imfinzi + Imjudo Approved In Japan For Advanced Liver, Biliary Tract And Lung Cancers
28 Dec 2022 07:44 GMT
… liver, biliary tract and lung cancers.
Imfinzi plus Imjudo has … and non-small cell lung cancers, and Imfinzi has been … recurrent non-small cell lung cancer or NSCLC in combination … in combination with chemotherapy (gemcitabine plus cisplatin).
Dave Fredrickson, …
-
CHMP recommends marketing approval for AstraZeneca's Imfinzi plus Imjudo to treat advanced liver and lung cancers
20 Dec 2022 06:19 GMT
… (EU) for advanced liver and lung cancers.
The concurrent positive opinions recommend … with metastatic non-small cell lung cancer in Europe.”
Susan Galbraith, … receiving chemotherapy (88.3%) received gemcitabine and platinum.
Primary endpoints included …
-
Lung Cancer Therapeutics Market is registering a CAGR of 10.41% and is Expected to Reach USD 54,475.11 Million by 2029
15 Dec 2022 18:15 GMT
… lung cancer are three different types of lung cancer. Global lung cancer … avastin, gemzar, taxotere … lung-cancer-therapeutics-market
Cancer Type
Non-Small Cell Lung Cancer
Metastatic Lung Cancer … cell lung cancer, metastatic lung cancer, …
-
Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy
05 Dec 2022 09:10 GMT
… in lung tumor–bearing … lung cancer combination therapy.Keywords: lung cancer, prodrug, etoposide, cisplatin, nanostructured lipid carriers
Introduction
Lung cancer … lung cancer (NSCLC; about 85%) and small-cell lung cancer … (Etp), gemcitabine, or vinorelbine …
-
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
11 Nov 2022 13:34 GMT
… (88.3%) received gemcitabine and platinum.
Primary … for people with lung cancer, including and beyond … @AstraZenecaUS.
References
Lungevity. Lung Cancer Statistics. Available at: https … -advocates/lung-cancer-awareness/lung-cancer-statistics#1. …
-
Imfinzi and Imjudo with chemotherapy approved in US for patients with metastatic non-small cell lung cancer
11 Nov 2022 07:15 GMT
… MD, Director of Lung Cancer Research, Sarah Cannon Research … Metastatic non-small cell lung cancer remains a significant treatment … (88.3%) received gemcitabine and platinum.
Primary endpoints … improvements for people with lung cancer, including and beyond …
About
© 1995-2023